Democratizing complex cardiac and brain stroke interventions with AI-driven mini-robotics
At Carvolix, we are transforming cardiac valve replacement and ischemic stroke treatment. We focus on conditions with large unmet clinical need and limited patient access to effective therapy.
Our Portfolio
At Carvolix, we are transforming cardiac valve replacement and ischemic stroke treatment.
Carvolix develops AI- and imaging-driven mini-robotic technologies designed to expand access to these life-saving procedures. Our platform supports interventional cardiologists in complex procedures, where precision, consistency, and speed are critical.
Our mini-robots operate with supervised autonomy, guided by real-time imaging and artificial intelligence. By assisting with navigation and positioning, they help clinicians manage the most technically demanding steps of valve and stroke interventions, with the goal of improving procedural efficiency, safety, and patient outcomes.
By empowering interventional cardiologists, far more numerous than surgeons and interventional neuroradiologists, and highly receptive to innovation, we expand patients’ access to advanced procedures. Our platform enables a broader base of physicians to perform complex interventions with greater precision, confidence, and reproducibility, ultimately accelerating patient access to life-saving therapies.
World First Autopilot Solutions for Heart & Brain Procedures
Heart Valve Replacement
17% of eligible patients receive TAVI
4% of patients with severe mitral regurgitation undergo surgery
Stroke Treatment
Less than 5% of ischemic stroke patients have access to mechanical thrombectomy
2nd cause of death • 1st cause of acquired handicap
Press Releases & Articles
Carvolix is born and funded
Carvolix is born and funded
February 2026
Caranx Medical announces first clinical use of the TAVIPILOT Soft, cleared by FDA for commercial in July: the world first AI Software for real-time intra-operative guidance of transcatheter heart valve implantation.
Caranx Medical announces first clinical use of the TAVIPILOT Soft, cleared by FDA for commercial in July: the world first AI Software for real-time intra-operative guidance of transcatheter heart valve implantation.
February 2026
Caranx Medical (Carvolix project company) announces first clinical use in patients of the TAVIPILOT Robot at Macquarie University Hospital, Sydney, Australia
Caranx Medical (Carvolix project company) announces first clinical use in patients of the TAVIPILOT Robot at Macquarie University Hospital, Sydney, Australia
February 2026
